Effectiveness of recombinant factor IX Fc prophylaxis for the treatment of haemophilia B: A systematic review of real-world evidence
Therapeutic Advances in Hematology · 2026-11 · 17
DOI: 10.1177/20406207261501415 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Therapeutic Advances in Hematology, online erschienen am 07.11.2026. Verfasst von Mairead O'Donovan und 8 weiteren Autor:innen. Die Arbeit nennt 81 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Sobi.
Abstract (Originalsprache)
Background
Recombinant factor IX Fc fusion protein (rFIXFc; eftrenonacog alfa) is an extended half-life factor IX (FIX) concentrate approved for prophylaxis and treatment of bleeding in people with haemophilia B (PwHB). While pivotal trials have established its efficacy and safety, real-world data are essential to assess its effectiveness across broader patient populations and clinical settings, reflecting routine clinical practice.
Objectives
To systematically review and synthesise published real-world evidence (RWE) on the effectiveness of rFIXFc prophylaxis in PwHB.
Design
A systematic literature review. Data sources and methods PubMed, MEDLINE, CINAHL, APA PsycInfo, AMED, Scopus and Web of Science databases were systematically searched from January 2014 to December 2025 for English-language observational studies reporting real-world outcomes with rFIXFc prophylaxis (PROSPERO CRD42023436868). Data were synthesised narratively.
Results
Twenty studies (36 publications), including 824 PwHB treated with rFIXFc (children/adolescents and adults with mixed disease severity), were included. rFIXFc prophylaxis was associated with consistently low annualised bleeding rates (median 0.0–4.0; 0.0–2.0 in most [9/12] studies), low joint and spontaneous bleeding rates, and sustained bleed protection. Intra-patient analyses showed reduced bleeding rates, injection frequency and factor consumption after switching from standard half-life-FIX to rFIXFc prophylaxis. Available evidence suggests effective perioperative haemostasis with rFIXFc and maintenance or improvement of health-related quality of life. rFIXFc also resolved pre-existing and prevented development of new target joints, and was associated with high treatment satisfaction. Inhibitor development was low (one reported case across 11 studies).
Conclusion
This systematic review provides a comprehensive synthesis of more than 10 years’ experience with rFIXFc in routine clinical practice. The RWE findings demonstrate the benefits of rFIXFc prophylaxis include effective bleed protection and reduced treatment burden, consistent with pivotal trials, and support its use across different age groups and disease severities in all clinical settings.
Förderung
- Sobi
Zitieren
APA
O'Donovan, M., Fatoye, F., Gebrye, T., Fatoye, C., Hakimi, Z., Bednar, E., Eriksson, D., Toumi, M., & Ay, C. (2026). Effectiveness of recombinant factor IX Fc prophylaxis for the treatment of haemophilia B: A systematic review of real-world evidence. Therapeutic Advances in Hematology, 17. https://doi.org/10.1177/20406207261501415
Vancouver
O'Donovan M, Fatoye F, Gebrye T, Fatoye C, Hakimi Z, Bednar E, et al. Effectiveness of recombinant factor IX Fc prophylaxis for the treatment of haemophilia B: A systematic review of real-world evidence. Therapeutic Advances in Hematology. 2026;17. doi:10.1177/20406207261501415
BibTeX
@article{ODonovan2026,
author = {O'Donovan, Mairead and Fatoye, Francis and Gebrye, Tadesse and Fatoye, Clara and Hakimi, Zalmai and Bednar, Eva and Eriksson, Daniel and Toumi, Mondher and Ay, Cihan},
title = {Effectiveness of recombinant factor IX Fc prophylaxis for the treatment of haemophilia B: A systematic review of real-world evidence},
journal = {Therapeutic Advances in Hematology},
year = {2026},
volume = {17},
doi = {10.1177/20406207261501415}
}
EUVIMED